According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ NSCLC patients in Beamion Lung-1, with 8% complete responses and 69% partial ...
The Galleri multi-cancer early detection (MCED) test – which looks for around 50 different types – achieved a seven-fold increase in cancer detection when added to standard screening tests for breast, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback